# US 2023/0271933 A1 · Heterocyclic immunomodulator

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0271933 A1
- Document ID: US20230271933A1
- Status: Published application
- Kind: A1
- Application number: 18/014,623
- Filed: 2021-06-28
- Published: 2023-08-31
- Earliest claimed: 2020-07-06
- Assignees: Beijing Innocare Pharma Tech Co., Ltd.
- Applicants: Beijing Innocare Pharma Tech Co., Ltd.
- Inventors: Xiangyang Chen; Yucheng Pang
- Web page: https://patentgrep.com/patent/US20230271933A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07D 401/14: containing three or more hetero rings
- C07D 491/08: Bridged systems
- C07B 2200/07: Optical isomers
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates to heterocyclic compounds as immunomodulators, or pharmaceutically acceptable salts thereof. Specifically, the present invention relates to compounds as represented by general formula (I) and pharmaceutically acceptable salts thereof. The present invention also relates to methods for preparing the compounds or the pharmaceutically acceptable salts thereof. The compounds can be used for treating and/or preventing tumors, inflammations or immune diseases.

## Claims

### Claim 1

A compound represented by general formula (I), or a pharmaceutically acceptable salt, a stable isotope derivative, or an isomer thereof:
wherein:
ring A is a nitrogen-containing 4- to 10-membered heterocycle;
R1 is D or halogen;
R2 and R3 are each independently selected from H, D, halogen, cyano, C1-6alkyl, C3-6cycloalkyl or 3- to 8-membered heterocyclyl, but both cannot be H and/or D at the same time, or R2 and R3 together with the carbon atoms attached thereto form C3-6cycloalkane or 3- to 8-membered heterocycle;
R4 is D, halogen, cyano, oxo, C1-6alkyl, C3-6cycloalkyl, —OC1-6alkyl, —C(O)C1-6alkyl, —C(O)C3-6cycloalkyl, —S(O)2C1-6alkyl, —S(O)2C3-6cycloalkyl, aryl or heteroaryl, wherein one or more hydrogens of the alkyl, the cycloalkyl, the aryl and the heteroaryl are optionally substituted with D, halogen, cyano, C1-2alkyl or fluoroC1-2alkyl;
m is an integer of 0-4; and
n is an integer of 0-2.

### Claim 2 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt, a stable isotope derivative, or an isomer thereof, wherein ring A is a 4- to 10-membered monocyclic heterocycle containing one N atom, or a fused-, bridged- or spiro-bicyclic heterocycle (such as morpholine, piperidine, thiomorpholine-1,1-dioxide, 2-oxa-5-azabicyclo[2.2.1]heptane, or the like); R4 is D, halogen, oxo, —CF3 or C1-6alkyl.

### Claim 3 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt, a stable isotope derivative, or an isomer thereof, wherein ring A is a 6- to 10-membered monocyclic heterocycle containing two N atoms, or a fused-, bridged- or spiro-bicyclic heterocycle (such as piperazine, 3,6-diazabicyclo[3.1.1]heptane, 2,6-diazaspiro[3.3]heptane, or the like), preferably ring A is piperazine; R4 is attached to the second N atom and is C1-6alkyl, C3-6cycloalkyl, —C(O)C1-6alkyl, —C(O)C3-6cycloalkyl, —S(O)2C1-6alkyl, —S(O)2C3-6cycloalkyl, phenyl, or 5- or 6-membered heteroaryl containing N, O and/or S, wherein one or more hydrogens of the alkyl, the cycloalkyl, the phenyl and the heteroaryl are optionally substituted with D, halogen, cyano, C1-2alkyl or fluoroC1-2alkyl; n is 0 or 1.

### Claim 4 (depends on 1, 2, 3)

The compound according to any of claims 1-3 or a pharmaceutically acceptable salt, a stable isotope derivative, or an isomer thereof, wherein R2 is H; R3 is cyano, C1-6alkyl or C3-6cycloalkyl, preferably R3 is methyl or cyano.

### Claim 5 (depends on 1, 2, 3)

The compound according to any of claims 1-3 or a pharmaceutically acceptable salt, a stable isotope derivative, or an isomer thereof, wherein both R2 and R3 are methyl.

### Claim 6 (depends on 1, 2, 3)

The compound according to any of claims 1-3 or a pharmaceutically acceptable salt, a stable isotope derivative, or an isomer thereof, wherein R2 and R3 together with the carbon atoms attached thereto form C3-6cycloalkane.

### Claim 7

The compound according to any of the previous claims or a pharmaceutically acceptable salt, a stable isotope derivative, or an isomer thereof, wherein m is 0.

### Claim 8 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt, a stable isotope derivative, or an isomer thereof, which is a compound represented by the following general formula (II):
wherein:
R5 is H, C1-6alkyl, C3-6cycloalkyl, —C(O)C1-6alkyl, —C(O)C3-6cycloalkyl, —S(O)2C1-6alkyl, phenyl or 5- to 6-membered heteroaryl containing N, O and/or S, wherein one or more hydrogens of the alkyl, the cycloalkyl, the phenyl and the heteroaryl are optionally substituted with D, halogen, cyano or C1-2alkyl, preferably R5 is phenyl, pyridinyl or pyrimidinyl, wherein one or two hydrogens of the phenyl, the pyridinyl and the pyrimidinyl are optionally substituted with F or cyano.

### Claim 9 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt, a stable isotope derivative or an isomer thereof, wherein the compound is selected from:

### Claim 10 (depends on 9)

The compound according to claim 9 which is:

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A pharmaceutical composition, which contains the compound according to any of claims 1-10 or a pharmaceutically acceptable salt, a stable isotope derivative, or an isomer thereof and a pharmaceutically acceptable carrier or adjuvant.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A pharmaceutical composition, which contains the compound according to any of claims 1-10 or a pharmaceutically acceptable salt, a stable isotope derivative, or an isomer thereof and at least one additional drug, wherein said at least one additional drug is selected from chemotherapeutic agents, immune and/or inflammation modulators, neurologically related disease modulators, and the like.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method for treating or preventing a correlated disease mediated by Aiolos, Ikaros, Helios, CK1α, GSPT1, IL-2, IL-6, TNFα, IFNγ, VEGF or the like, wherein said method comprises administrating a therapeutically effective amount of the compound according to any of claims 1-12 or a pharmaceutically acceptable salt, a stable isotope derivative, or an isomer thereof, or a pharmaceutical composition containing the compound to a subject in need thereof, said disease includes, but is not limited to, hematological tumors, solid tumors, autoimmune diseases, inflammations, neurodegenerative diseases, skin diseases, or the like.
